Scailyte and MaxiVAX Solve Clinical Challenges with Data-Driven Collaboration

Jul 5 2023

Scailyte and MaxiVAX proudly announce their collaboration to improve patient outcomes.

Scailyte and MaxiVAX, two cutting-edge precision medicine organizations, proudly announce their collaboration to improve patient outcomes.

Recognizing the potential of data-driven insights in informing and improving clinical outcomes, MaxiVAX sought a partner with expertise in data analytics. In this collaboration, Scailyte conducted a retrospective multi-omic analysis of phase IIa clinical single arm trial data for MaxiVAX’s lead cancer vaccine candidate, with the goal of characterizing the biological determinants of patient response.

By integrating advanced data analytics into MaxiVAX clinical programs, the collaboration has yielded valuable insights that shed light on the benefit:risk ratio of their clinical candidate, supporting decisions related to the clinical development of this molecule.

“Scailyte has deployed advanced AI and analytics to key clinical data, with the aim of unveiling relevant insights to support MaxiVAX’ decisions on the next development milestones,” said Corinne Solier, SVP Corporate & Technology Development at Scailyte. “With a commitment to scientific rigor and excellence, this partnership exemplified the power of data-driven decision-making”.

“Scailyte has been instrumental in analyzing phase IIa clinical single arm trial data of our most advanced development program” said Thomas Mehrling, MD PhD, CEO of MaxiVAX. “Scailyte’s scientific expertise, communication style and agility are commendable”, added Thomas.

Moving forward, Scailyte and MaxiVAX remain committed to pushing the boundaries of innovation and unlocking the potential of data-driven healthcare for the betterment of patient prognoses.

About Scailyte

Scailyte is a Swiss-based start-up specialized in generating actionable insights/biosignatures from multi-omics single-cell data using artificial intelligence (AI). Our AI platform, ScaiVision, combines features to integrate different datasets, is indication- and cell-type agnostic and uses data augmentation and a cluster-free approach to extract relevant information while retaining single-cell resolution. These features result in very high discovery success rates from a limited number of samples, with actionable insights for the basis of assay development.

With a commitment to excellence, Scailyte empowers partners to transform data into actionable intelligence informing decision making and driving innovation.

For more information, visit www.scailyte.com and connect on social media @LinkedIn and @Twitter.

ScailyteTM and ScaiVisionTM are registered trademarks proprietary to Scailyte AG.

About MaxiVAX

MaxiVAX is a clinical-stage biotechnology company advancing patient-specific immunomodulatory strategies for the treatment of cancers. The company was founded in 2005 and is dedicated to efficiently progressing potential best-in-class anti-cancer immunotherapies to address significant unmet medical needs and improve outcomes for people with difficult-to-treat cancer.

For more information, visit www.maxivax.ch and connect on @LinkedIn.

Recent News

Scailyte and Sanofi Collaboration Solves Critical Manufacturing Challenge for NK Cell Therapy, New Paper Reveals

Scailyte's AI-driven ScaiVision™ platform successfully identified a predictive biomarker for manuf...

Scailyte Awarded CHF 800K Innosuisse Grant to Drive Precision Medicine in Inflammatory Bowel Disease (IBD)

Project AIomics will unite Scailyte's AI discovery platform with the Swiss IBD Cohort and Universit�...

Scailyte and Visterra Partner to Advance Autoimmune Disease Research

Scailyte AG, an AI-driven biomarker discovery company, and Visterra, Inc., a clinical-stage biopharm...

Scailyte Strengthens Its Leadership

Scailyte appoints Tim Foley as Chief Business Officer, Jean-Pierre Rosat as Executive Chair, and Dar...

Scailyte Announces Virginia Savova, PhD as a Strategic and Scientific Advisor

Scailyte Announces Virginia Savova, PhD as a Strategic and Scientific Advisor. Dr. Savova brings str...

Scailyte Extends Series A to USD 8 Million

We are thrilled to announce the extension of our Series A funding, bringing the total raised amount ...

Unravelling the AI Executive Order: A Discussion with Our CEO and Head of Regulatory Affairs

We invite you to watch this enlightening discussion to gain valuable insights into the evolving AI l...